肝细胞癌代谢重编程研究进展

doi:10.3969/j.issn.1004-583X.2025.12.015

摘要/Abstract

摘要：

肝细胞癌（hepatocellular carcinoma，HCC）是全球发病率和死亡率较高的恶性肿瘤，其预后较差与早期诊断困难及缺乏有效治疗手段密切相关。代谢重编程作为HCC的重要特征，通过改变葡萄糖、脂质和氨基酸代谢，满足肿瘤细胞快速增殖及适应肿瘤微环境的需求。本综述系统阐述了HCC中三大代谢途径的异常改变及其分子机制：葡萄糖代谢以Warburg效应为主，伴有戊糖磷酸途径激活和糖异生抑制；脂质代谢涉及脂肪酸摄取、合成及氧化的重构；氨基酸代谢则主要表现为谷氨酰胺代谢亢进和尿素循环失调。这些代谢异常不仅促进肿瘤生长和转移，还通过代谢物积累和营养竞争重塑肿瘤免疫微环境，诱导免疫逃逸。基于上述机制，本文进一步总结了靶向代谢关键酶、转运蛋白及相关信号通路的治疗策略，为开发新型HCC治疗方法提供了理论依据和转化方向。

关键词: 肝肿瘤, 代谢重编程, 机制, 治疗

中图分类号:

R735.7

邢路超, 苑建磊. 肝细胞癌代谢重编程研究进展[J]. 临床荟萃, 2025, 40(12): 1136-1141.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.12.015

https://www.lchc.cn/CN/Y2025/V40/I12/1136

参考文献 61

[1]	Llovet JM, Kelley RK, Villanueva A, et al. Author correction: Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2024, 10(1):10.doi: 10.1038/s41572-024-00500-6. pmid: 38346997
[2]	杨嘉睿, 江建新. 《2024年欧洲肝病学会临床实践指南:肝细胞癌管理》摘译[J]. 临床肝胆病杂志, 2025, 41(2): 234-239. doi:10.12449/JCH250207.
[3]	Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer[J]. Cell Metab, 2019, 30(3): 434-446. doi: 10.1016/j.cmet.2019.08.013. pmid: 31484055
[4]	Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate[J]. Cancer Cell, 2012, 21(3): 297-308. doi: 10.1016/j.ccr.2012.02.014. pmid: 22439925
[5]	Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930): 1029-1033. doi: 10.1126/science.1160809. pmid: 19460998
[6]	Li C, Chen J, Li Y, et al. 6-Phosphogluconolactonase promotes hepatocellular carcinogenesis by activating pentose phosphate pathway[J]. Front Cell Dev Biol, 2021, 9: 753196. doi: 10.3389/fcell.2021.753196.eCollection 2021.
[7]	Zhang J, Zhang Z, Wu Z, et al. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma[J]. Chin Med J (Engl), 2024, 137(11): 1271-1284. doi: 10.1097/CM9.0000000000003144. Epub 2024 May 13.
[8]	Wang J, Wang H, Gao M, et al. The regulation of amino acid metabolism in tumor cell death: From the perspective of physiological functions[J]. Apoptosis, 2023, 28(9-10): 1304-1314. doi: 10.1007/s10495-023-01875-9. Epub 2023 Jul 31.
[9]	Caini P, Carloni V. Metabolism and immune suppressive response in liver cancer[J]. Biomedicines, 2025, 13(6):1461. doi: 10.3390/biomedicines13061461.
[10]	Lan Q, Ouyang A, Chen Y, et al. Pain, lactate, and anesthetics: Intertwined regulators of tumor metabolism and immunity[J]. Front Oncol, 2025, 15: 1534300. doi: 10.3389/fonc.2025.1534300.eCollection2025.
[11]	夏宁, 刘丽华. 低氧诱导因子促进恶性肿瘤免疫逃逸的机制及其临床转化[J]. 中国肿瘤生物治疗杂志, 2021, 28(11): 1129-1134.doi: 10.3872/j.issn.1007-385x.2021.11.011.
[12]	Lee NCW, Carella MA, Papa S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer[J]. Front Cell Dev Biol, 2018, 6: 138. doi: 10.3389/fcell.2018.00138. eCollection 2018. pmid: 30430110
[13]	Zhang C, Liu Z, Wang F, et al. Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion[J]. Drug Deliv, 2023, 30(1): 2162160. doi: 10.1080/10717544.2022.2162160.
[14]	Yin Q, Yao Y, Ni J, et al. DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis[J]. Mol Med, 2025, 31(1): 71. doi: 10.1186/s10020-025-01125-5. pmid: 39979835
[15]	He K, Tao F, Lu Y, et al. The role of HK2 in tumorigenesis and development: Potential for targeted therapy with natural products[J]. Int J Med Sci, 2025, 22(4): 790-805. doi: 10.7150/ijms.105553. eCollection 2025. pmid: 39991762
[16]	Yu T, Liu Z, Tao Q, et al. Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming[J]. Cancer Lett, 2024, 589: 216824. doi: 10.1016/j.canlet.2024.216824. Epub 2024 Mar 22.
[17]	Kam CS, Ho DW, Ming VS, et al. PFKFB4 drives the oncogenicity in TP53-mutated hepatocellular carcinoma in a phosphatase-dependent manner[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(6): 1325-1350. doi: 10.1016/j.jcmgh.2023.02.004. pmid: 36806581
[18]	Yang W, Wang Y, Tao K, et al. Metabolite itaconate in host immunoregulation and defense[J]. Cell Mol Biol Lett, 2023, 28(1): 100. doi: 10.1186/s11658-023-00503-3. pmid: 38042791
[19]	Mahmoudvand S, Sheikhrobat SB, Shokri S, et al. From immunity to oncology: Itaconic acid as a driver in HBV-induced HCC[J]. J Cell Mol Med, 2025, 29(12): e70612. doi: 10.1111/jcmm.70612.
[20]	Li F, Wang B, Li H, et al. G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma[J]. BMC Cancer, 2024, 24(1): 157. doi: 10.1186/s12885-024-11887-6. pmid: 38297250
[21]	Zeng T, Li B, Shu X, et al. Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers[J]. Front Oncol, 2023, 13: 1183474. doi: 10.3389/fonc.2023.1183474. eCollection 2023.
[22]	Gu XY, Zhou ZJ, Yao H, et al. The role of transketolase in the immunotherapy and prognosis of hepatocellular carcinoma: A multi-omics approach[J]. Front Immunol, 2025, 16: 1529029. doi: 10.3389/fimmu.2025.1529029. eCollection 2025.
[23]	Gu L, Zhu Y, Nandi SP, et al. FBP1 controls liver cancer evolution from senescent MASH hepatocytes[J]. Nature, 2025, 637(8045): 461-469. doi: 10.1038/s41586-024-08317-9. Epub 2025 Jan 1.
[24]	Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression[J]. J Clin Invest, 2023, 133(13): e161713. doi: 10.1172/JCI161713.
[25]	Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer[J]. Br J Cancer, 2020, 122(1): 4-22. doi: 10.1038/s41416-019-0650-z. Epub 2019 Dec 10.
[26]	Pan B, Chen S, Wu H, et al. Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer[J]. Theranostics, 2025, 15(12): 5931-5952. doi: 10.7150/thno.110567. eCollection 2025. pmid: 40365281
[27]	Cyriac R, Lee K. Glutaminase inhibition as potential cancer therapeutics: Current status and future applications[J]. J Enzyme Inhib Med Chem, 2024, 39(1): 2290911. doi: 10.1080/14756366.2023.2290911. Epub 2023 Dec 11.
[28]	Su F, Koeberle A. Regulation and targeting of SREBP-1 in hepatocellular carcinoma[J]. Cancer Metastasis Rev, 2024, 43(2): 673-708. doi: 10.1007/s10555-023-10156-5. Epub 2023 Dec 1.
[29]	林叶昕, 陈科, 安方梅, 等. 肝细胞癌患者脂代谢异常分析及脂肪酸结合蛋白的表达意义研究[J]. 中华肝脏病杂志, 2021, 29(10): 1006-1013. doi: 10.3760/cma.j.cn501113-20200416-00189.
[30]	Liu Y, Wang F, Yan G, et al. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer[J]. Cancer Lett, 2024, 595: 217006. doi: 10.1016/j.canlet.2024.217006. Epub 2024 May 31.
[31]	Yu HC, Bai L, Jin L, et al. SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α[J]. Cell Commun Signal, 2025, 23(1): 130. doi: 10.1186/s12964-025-02109-y.
[32]	Xu M, Xie P, Liu S, et al. LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation[J]. Cancer Lett, 2025, 612: 217469. doi: 10.1016/j.canlet.2025.217469. Epub 2025 Jan 20.
[33]	Matsufuji S, Kitajima Y, Higure K, et al. A HIF-1α inhibitor combined with palmitic acid and L-carnitine treatment can prevent the fat metabolic reprogramming under hypoxia and induce apoptosis in hepatocellular carcinoma cells[J]. Cancer Metab, 2023, 11(1): 25. doi: 10.1186/s40170-023-00328-w. pmid: 38066600
[34]	Liu X, Ren B, Ren J, et al. The significant role of amino acid metabolic reprogramming in cancer[J]. Cell Commun Signal, 2024, 22(1): 380. doi: 10.1186/s12964-024-01760-1. pmid: 39069612
[35]	Ziki RA, Colnot S. Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma[J]. JHEP Rep, 2024, 6(5): 101077. doi: 10.1016/j.jhepr.2024.101077. eCollection 2024 May.
[36]	Sun Y, Shen Y, Yan Y, et al. GLS1 promotes lipid metabolism in hepatocellular carcinoma by regulating the PI3K/AKT/mTORC1 signaling pathway through SREBP-1[J]. Am J Transl Res, 2025, 17(4): 2527-2540. doi: 10.62347/ZTGP5030. eCollection 2025.
[37]	Tambay V, Raymond VA, Voisin L, et al. Reprogramming of glutamine amino acid transporters expression and prognostic significance in hepatocellular carcinoma[J]. Int J Mol Sci, 2024, 25(14): 7558. doi: 10.3390/ijms25147558.
[38]	Zhang Q, Wei T, Jin W, et al. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism[J]. J Hepatol, 2024, 80(2): 293-308. doi: 10.1016/j.jhep.2023.10.024. Epub 2023 Oct 30. pmid: 38450598
[39]	Hajaj E, Sciacovelli M, Frezza C, et al. The context-specific roles of urea cycle enzymes in tumorigenesis[J]. Mol Cell, 2021, 81(18): 3749-3759. doi: 10.1016/j.molcel.2021.08.005. Epub 2021 Aug 31. pmid: 34469752
[40]	Mossmann D, Müller C, Park S, et al. Arginine reprograms metabolism in liver cancer via RBM39[J]. Cell, 2023, 186(23): 5068-5083. doi: 10.1016/j.cell.2023.09.011. Epub 2023 Oct 6. pmid: 37804830
[41]	Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5): 1773-1796. doi: 10.1002/hep.32740. Epub 2023 Apr 17.
[42]	Surjan RCT, de Lima TM, de Souza HP, et al. Molecular basis of hyperammonemic encephalopathy in fibrolamellar hepatocellular carcinoma[J]. Cureus, 2023, 15(1): e33750. doi: 10.7759/cureus.33750. eCollection 2023 Jan.
[43]	He L, Cai X, Cheng S, et al. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma[J]. Oncol Lett, 2019, 17(6): 5030-5038. doi: 10.3892/ol.2019.10174. Epub 2019 Mar 21. pmid: 31186714
[44]	Dong F, He K, Zhang S, et al. SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1[J]. Cell Rep, 2024, 43(10): 114818. doi: 10.1016/j.celrep.2024.114818. Epub 2024 Oct 9.
[45]	Hu Y, Xing Y, Fan G, et al. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis[J]. Front Pharmacol, 2024, 15: 1391636. doi: 10.3389/fphar.2024.1391636. eCollection 2024.
[46]	Zhong W, Chen T, Chen L, et al. Crippled hepatocarcinogenesis inhibition of quercetin in glycolysis pathway with hepatic farnesoid X receptor deficiency[J]. Curr Pharm Des, 2025, 31(22): 1800-1815. doi: 10.2174/0113816128342642250111055339.
[47]	Lin C, Wan Y, Huo Q, et al. Chemoproteomics reveals Ailanthone directly binds to PKM2 to inhibit the progression of hepatocellular carcinoma[J]. Phytomedicine, 2025, 143: 156886. doi: 10.1016/j.phymed.2025.156886. Epub 2025 May 21.
[48]	Fei M, Li X, Liang S, et al. LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity[J]. Cancer Lett, 2024, 584: 216620.doi: 10.1016/j.canlet.2024.216620. Epub 2024 Jan 11.
[49]	Li X, Peng X, Li Y, et al. Glutamine addiction in tumor cell: Oncogene regulation and clinical treatment[J]. Cell Commun Signal, 2024, 22(1): 12. doi: 10.1186/s12964-023-01449-x. pmid: 38172980
[50]	Gallage S, Ali A, Barragan Avila JE, et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1[J]. Cell Metab, 2024, 36(6): 1371-1393. doi: 10.1016/j.cmet.2024.04.015. Epub 2024 May 7.
[51]	Huang J, Tsang WY, Fang XN, et al. FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma[J]. Cancer Res, 2024, 84(6): 855-871. doi: 10.1158/0008-5472.CAN-23-0966. pmid: 38486485
[52]	Chang W, Wang J, You Y, et al. Triptolide reduces neoplastic progression in hepatocellular carcinoma by downregulating the lipid lipase signaling pathway[J]. Cancers (Basel), 2024, 16(3): 550. doi: 10.3390/cancers16030550.
[53]	Tu DY, Peng R, Jin SJ, et al. MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis[J]. Cell Death Dis, 2025, 16(1): 391. doi: 10.1038/s41419-025-07707-9.
[54]	He W, Wang M, Zhang X, et al. Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development[J]. Cancer Res, 2024, 84(15): 2417-2431. doi: 10.1158/0008-5472.CAN-23-3966.
[55]	Tzeng SF, Yu YR, Park J, et al. PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis[J]. Cancer Discov, 2025, 15(8): 1676-1696. doi: 10.1158/2159-8290.CD-24-1409.
[56]	Ren M, Xu H, Xia H, et al. Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis[J]. Cell Death Discov, 2021, 7(1): 125. doi: 10.1038/s41420-021-00504-1. pmid: 34052835
[57]	Liu Z, You Y, Chen Q, et al. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis[J]. Mol Ther, 2022, 30(2): 606-620. doi: 10.1016/j.ymthe.2021.07.015. Epub 2021 Oct 1.
[58]	Ghosh A, Ghosh AK, Zaman A, et al. Metformin-loaded hyaluronic acid-derived carbon dots for targeted therapy against hepatocellular carcinoma by glutamine metabolic reprogramming[J]. Mol Pharm, 2023, 20(12): 6391-6406.doi: 10.1021/acs.molpharmaceut.3c00772. Epub 2023 Nov 7.
[59]	Prasad YR, Anakha J, Pande AH. Treating liver cancer through arginine depletion[J]. Drug Discov Today, 2024, 29(4): 103940.doi: 10.1016/j.drudis.2024.103940. Epub 2024 Mar 6.
[60]	Li A, Cui H, Zhao E. Targeting RNA-binding motif protein 39 for arginine reduction: unveiling metabolic vulnerability in arginine-dependent liver cancer[J]. MedComm (2020), 2024, 5(7): e581. doi: 10.1002/mco2.581. eCollection 2024 Jul.
[61]	Ning M, Zhu Y, Miao R, et al. A biomimetic nanomedicine for remodeling the immune microenvironment to potentiating anti-tumor therapy[J]. Adv Healthc Mater, 2025: e2501457. doi: 10.1002/adhm.202501457. Epub 2025 Jun 30.

肝细胞癌代谢重编程研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 61

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘炎, 严晓华, 焦富勇. 川崎病流行病学现状、争议及展望[J]. 临床荟萃, 2025, 40(9): 861-864.
[2]	赵伟, 徐慧娟, 赵艳霞, 王玲珍, 卢愿, 杨静. 婴儿恶性石骨症1例并文献复习[J]. 临床荟萃, 2025, 40(8): 726-730.
[3]	陈文江, 舒展, 周来显. 基于核酸适配体的肺癌诊断和治疗研究进展[J]. 临床荟萃, 2025, 40(8): 742-747.
[4]	孙楠, 杨凯琦, 唐亚赛, 谢小华, 吕佩源, 董艳红. 帕金森病认知障碍的治疗新进展[J]. 临床荟萃, 2025, 40(8): 748-752.
[5]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.
[6]	卢远思, 吕见君, 官计彬, 操龙斌. 双相情感障碍患者外周血中FGF1的表达与糖脂代谢的相关性[J]. 临床荟萃, 2025, 40(7): 619-623.
[7]	孙振晓, 于相芬. 皮肤搔抓障碍的研究进展[J]. 临床荟萃, 2025, 40(7): 647-652.
[8]	毛静静, 兰云霞, 陈鲁玉, 宋先荣. A型主动脉夹层合并肠系膜上动脉缺血的研究进展[J]. 临床荟萃, 2025, 40(7): 659-662.
[9]	何媛, 王俭. 特发性脊柱侧凸患者神经与结构影像相关改变的研究进展[J]. 临床荟萃, 2025, 40(7): 669-672.
[10]	林彬城, 林刚曦. 病因、术前病程对药物难治性癫痫患儿疗效的影响[J]. 临床荟萃, 2025, 40(6): 527-531.
[11]	王思晗, 李向红, 李亮亮, 锡洪敏, 杨萍, 马丽丽, 尹向云. 新生儿RYR1相关肌病1例并文献复习[J]. 临床荟萃, 2025, 40(6): 541-546.
[12]	李云翔, 李淑琼, 丁雪, 王思博, 王建军. TLR2与肺炎支原体感染及药物治疗的研究进展[J]. 临床荟萃, 2025, 40(6): 553-557.
[13]	孙振晓, 于相芬. 幻肢痛的临床治疗进展[J]. 临床荟萃, 2025, 40(6): 570-576.
[14]	刘萍, 于猛, 刘明新, 李文锋. 血常规衍生的新型炎症指标与急性前壁ST段抬高型心肌梗死患者PCI术后院内发生不良心血管事件的相关性[J]. 临床荟萃, 2025, 40(5): 400-407.
[15]	赵雅静, 陶千山, 沈元元, 董毅. 地西他滨维持治疗对适合强化疗中低危急性髓细胞白血病患者生存的影响[J]. 临床荟萃, 2025, 40(5): 439-444.